MANKIND logo

Mankind Pharma Limited Stock Price

NSEI:MANKIND Community·₹896.7b Market Cap
  • 3 Narratives written by author
  • 0 Comments on narratives written by author
  • 16 Fair Values set on narratives written by author

MANKIND Share Price Performance

₹2,172.10
-826.30 (-27.56%)
₹2,150.00
Fair Value
₹2,172.10
-826.30 (-27.56%)
1.0% overvalued intrinsic discount
₹2,150.00
Fair Value
Price ₹2,172.10
AnalystLowTarget ₹2,150.00
AnalystConsensusTarget ₹2,699.12
AnalystHighTarget ₹3,260.00

MANKIND Community Narratives

AnalystLowTarget·
Fair Value ₹2.15k 1.0% overvalued intrinsic discount

Rising Regulatory Hurdles And Pricing Restrictions Will Undermine Future Prospects

0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
AnalystConsensusTarget·
Fair Value ₹2.7k 19.5% undervalued intrinsic discount

Chronic Therapy Demand And E-Commerce Will Fuel Future Expansion

0users have liked this narrative
0users have commented on this narrative
12users have followed this narrative
AnalystHighTarget·
Fair Value ₹3.26k 33.4% undervalued intrinsic discount

India's Rising Middle Class And Urbanization Will Reshape Healthcare Markets

0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
₹3.26k
33.4% undervalued intrinsic discount
Revenue
15.79% p.a.
Profit Margin
19.75%
Future PE
50.08x
Price in 2028
₹4.66k
₹2.7k
19.5% undervalued intrinsic discount
Revenue
12.97% p.a.
Profit Margin
18.65%
Future PE
47.29x
Price in 2028
₹3.86k
₹2.15k
1.0% overvalued intrinsic discount
Revenue
13.26% p.a.
Profit Margin
16.78%
Future PE
44.13x
Price in 2028
₹3.08k

Trending Discussion

Updated Narratives

MANKIND logo

MANKIND: Strong Profitability Outlook Will Support Future Bullish Re-Rating

Fair Value: ₹3.26k 33.4% undervalued intrinsic discount
0 users have followed this narrative
0 users have commented on this narrative
0 users have liked this narrative
MANKIND logo

MANKIND: Rising Margins And Upcoming Results Will Drive Further Upside

Fair Value: ₹2.7k 19.5% undervalued intrinsic discount
12 users have followed this narrative
0 users have commented on this narrative
0 users have liked this narrative
MANKIND logo

Rising Regulatory Hurdles And Pricing Restrictions Will Undermine Future Prospects

Fair Value: ₹2.15k 1.0% overvalued intrinsic discount
0 users have followed this narrative
0 users have commented on this narrative
0 users have liked this narrative

Snowflake Analysis

Excellent balance sheet with reasonable growth potential.

1 Risk
2 Rewards

Mankind Pharma Limited Key Details

₹135.5b

Revenue

₹40.9b

Cost of Revenue

₹94.5b

Gross Profit

₹77.0b

Other Expenses

₹17.5b

Earnings

Last Reported Earnings
Sep 30, 2025
Next Reporting Earnings
n/a
42.36
69.78%
12.91%
53.5%
View Full Analysis

About MANKIND

Founded
1991
Employees
26978
CEO
Sheetal Arora
WebsiteView website
www.mankindpharma.com

Mankind Pharma Limited develops, manufactures, and markets pharmaceutical formulations and consumer healthcare products in India and internationally. The company develops pharmaceuticals for acute and chronic therapeutics in the areas of anti-infective, cardiovascular, gastrointestinal, gynaecology, anti-diabetic, dermatology, pain/analgesics, neuro/CNS, vitamins/minerals/nutrients, respiratory diseases, etc. It also provides consumer healthcare products, such as condoms, pregnancy detection kits, oral contraceptives, antacid powders, vitamin and mineral supplements, and anti-acne preparations. In addition, the company engages in the trading and exporting of pharmaceutical and health care products; manufacture of packing materials, ayurvedic products, and consumer goods; real estate, leasing, and hospitality businesses; trading of agricultural products; and provision of IT services. It offers its products under the Manforce, Moxi Kind-Cv, AmLokind-At, Unwanted-Kit, Prega News, Dydroboon, Gudcef, Candi Force, Glimestar-M, Telmikind-Am, Nurokind-Gold, Telmikind-H, Nurokind-Lc, Telmikind, Vomikind, Cefakind, Nurokind Plus-Rf, Gudcef-Cv, Monticope, and Asthakind-Dx brand names. Mankind Pharma Limited was incorporated in 1991 and is based in New Delhi, India.

Recent MANKIND News & Updates

Recent updates

No updates